Drug Biotransformation: Overview

Lipophilic drugs are poorly eliminated by the kidneys because they are rapidly reabsorbed from the glomerular filtrate back into the bloodstream through drug elimination by renal route tubular reabsorption. This reabsorption causes drug accumulation in the body, prolonging effects and triggering toxic reactions. Biotransformation converts lipophilic drugs into hydrophilic derivatives, enabling efficient elimination through urine and preventing harmful accumulation.

The liver is the primary site for drug biotransformation, though other body tissues can also metabolize drugs. Specialized enzymes in the liver catalyze the sequential phase I and phase II reactions that convert lipophilic drugs into water-soluble metabolites. This hepatic metabolism is essential for preparing drugs for efficient elimination from the body.

Phase I reactions are catabolic and involve functionalization, introducing or exposing functional groups like hydroxyl, amino, or carboxyl groups to the drug molecule. Phase II reactions are anabolic and involve conjugation, adding water-soluble molecules such as glucuronic acid, sulfate, or glutathione. Together, these sequential reactions progressively increase drug water solubility for elimination.

Drugs are predominantly lipophilic and nonionized, allowing them to pass through lipid bilayers and reach intracellular target receptors. This lipophilic nature is advantageous for crossing biological barriers and reaching sites of action. However, this same property limits renal excretion, necessitating biotransformation into hydrophilic derivatives for elimination.

Biotransformation generally terminates a drug's biological activity by converting it into inactive metabolites. However, prodrugs represent an exception where biotransformation enhances activity rather than eliminating it. In prodrugs, metabolism converts an inactive compound into an active form, leading to improved therapeutic outcomes and more effective treatment.

Phase I reactions introduce or expose functional groups such as hydroxyl (-OH), amino (-NH2), or carboxyl (-COOH) groups to the drug molecule. These functionalization reactions create more polar metabolites than the parent drug, preparing the molecule for phase II conjugation reactions that further increase water solubility.

Phase II conjugation reactions add larger, water-soluble molecules to drugs or their phase I metabolites, including glucuronic acid, sulfate, or glutathione. These conjugation reactions significantly increase the drug's water solubility and prepare it for efficient elimination from the body through urine.